T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.57B |
| 2 |
Elevance Health
ELV
|
+$1.16B |
| 3 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$1.01B |
| 4 |
Royal Caribbean
RCL
|
+$860M |
| 5 |
AET
Aetna Inc
AET
|
+$790M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baidu
BIDU
|
+$1.76B |
| 2 |
Biogen
BIIB
|
+$1.47B |
| 3 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$1.26B |
| 4 |
McKesson
MCK
|
+$1.2B |
| 5 |
Sherwin-Williams
SHW
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.75% |
| 2 | Consumer Discretionary | 14.84% |
| 3 | Financials | 13.9% |
| 4 | Technology | 11.11% |
| 5 | Industrials | 9.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lowe's Companies
LOW
$124B
| $3B | 0.67% |
43,595,758
-3,511,959
| -7% | -$242M |
|
27
Thermo Fisher Scientific
TMO
$224B
| $2.91B | 0.65% |
23,807,307
+2,456,850
| +12% | +$320M |
|
28
AutoZone
AZO
$49.7B
| $2.86B | 0.64% |
3,947,671
+17,056
| +0.4% | +$12.1M |
|
29
American Tower
AMT
$79B
| $2.85B | 0.63% |
32,393,124
-557,886
| -2% | -$52.5M |
|
30
Intuitive Surgical
ISRG
$142B
| $2.81B | 0.63% |
55,066,860
+562,194
| +1% | +$31.8M |
|
31
Salesforce
CRM
$162B
| $2.72B | 0.61% |
39,244,796
-1,731,135
| -4% | -$123M |
|
32
Bristol-Myers Squibb
BMY
$130B
| $2.48B | 0.55% |
41,928,627
+8,426,181
| +25% | +$535M |
|
33
Walt Disney
DIS
$179B
| $2.48B | 0.55% |
24,230,772
+1,403,828
| +6% | +$153M |
|
|
BNY
34
Bank of New York Mellon
BNY
$109B
| $2.39B | 0.53% |
61,048,236
+9,896,404
| +19% | +$411M |
|
35
Intercontinental Exchange
ICE
$84.9B
| $2.32B | 0.52% |
49,354,720
+3,565,505
| +8% | +$165M |
|
36
Roper Technologies
ROP
$39.5B
| $2.32B | 0.52% |
14,788,326
-422,624
| -3% | -$69.9M |
|
37
ExxonMobil
XOM
$657B
| $2.27B | 0.5% |
30,496,203
+4,094,730
| +16% | +$316M |
|
38
Becton Dickinson
BDX
$49.4B
| $2.23B | 0.5% |
17,257,183
+2,702,070
| +19% | +$377M |
|
39
Regeneron Pharmaceuticals
REGN
$82.1B
| $2.23B | 0.5% |
4,798,155
+551,370
| +13% | +$296M |
|
40
FirstEnergy
FE
$27.1B
| $2.21B | 0.49% |
70,587,504
+9,316,748
| +15% | +$305M |
|
41
Starbucks
SBUX
$122B
| $2.18B | 0.49% |
38,423,073
-8,009,535
| -17% | -$449M |
|
42
PG&E
PCG
$38.1B
| $2.14B | 0.48% |
40,451,940
+7,024,016
| +21% | +$359M |
|
43
CVS Health
CVS
$120B
| $2.12B | 0.47% |
21,979,439
+1,899,084
| +9% | +$200M |
|
44
Incyte
INCY
$24.5B
| $2.12B | 0.47% |
19,202,896
-1,546,633
| -7% | -$173M |
|
45
State Street
STT
$51.4B
| $2.06B | 0.46% |
30,656,281
+3,022,426
| +11% | +$225M |
|
46
Cigna
CI
$72.4B
| $2.06B | 0.46% |
15,255,194
-4,289,766
| -22% | -$623M |
|
47
Tesla
TSLA
$1.31T
| $1.99B | 0.44% |
120,171,585
+12,827,805
| +12% | +$218M |
|
|
LNKD
48
DELISTED
LinkedIn Corporation
LNKD
| $1.91B | 0.43% |
10,072,041
+1,327,858
| +15% | +$264M |
|
49
Johnson & Johnson
JNJ
$626B
| $1.9B | 0.42% |
20,381,476
+1,444,505
| +8% | +$140M |
|
50
Wells Fargo
WFC
$264B
| $1.86B | 0.41% |
36,266,653
-7,085,843
| -16% | -$390M |
|
Similar funds
T. Rowe Price Associates's Q3 2015 Portfolio in Review
As of Q3 2015, T. Rowe Price Associates held 2,618 positions worth $449B, down 7.6% from $486B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q3 2015 filing shows 86 new, 1,108 increased, 800 reduced and 108 closed positions. Its largest new stake was BAXALTA INC COM STK (DE): 29,330,491 shares worth $924M. The largest sale was Baidu, an estimated $1.76B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q3 2015 buy was BAXALTA INC COM STK (DE): 29,330,491 shares worth $924M.
- T. Rowe Price Associates added most to Microsoft in Q3 2015, an estimated $1.57B increase.
- T. Rowe Price Associates's biggest Q3 2015 reduction was Baidu, cutting an estimated $1.76B.
- T. Rowe Price Associates fully exited HOSPIRA INC in Q3 2015, selling an estimated $988M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $449B portfolio in Q3 2015.
- T. Rowe Price Associates opened 86 new positions and closed 108 in Q3 2015.
- T. Rowe Price Associates's portfolio value fell 7.6% quarter-over-quarter to $449B.
Based on T. Rowe Price Associates's 13F filing for Q3 2015, filed 13 Nov 2015.